Every year on October 15th, we pay special attention to the topic of breast cancer – a disease that affects an increasing number of women. European Breast Cancer Awareness Day is not only a symbolic date, but above all an opportunity to highlight the critical importance of early disease detection and access to modern diagnostic and therapeutic methods. This is also a moment to emphasize that medical progress is made possible through scientific research, which leads to the development of more effective and safer diagnostic methods.
State-of-the-Art Imaging Technologies in Our Facility
Our facility is equipped with state-of-the-art PET/MR and PET/CT scanners, as well as the capability to perform whole-body magnetic resonance imaging (WBMR). These advanced diagnostic methods allow comprehensive evaluation of the entire body, detection of even the smallest neoplastic lesions, and precise assessment of metastases in the bones and internal organs such as the liver and brain.
We are currently conducting a research study involving patients with a preliminary diagnosis of breast cancer at least stage IIA (according to the TNM classification), confirmed histopathologically. The aim of the study is to accurately determine disease staging prior to treatment, while simultaneously minimizing patient exposure to radiation.
The study is funded by the Medical Research Agency as part of a non-commercial clinical research grant, conducted by the Medical University of Białystok. The project aims to compare the clinical value of innovative whole-body imaging techniques, WBMR and PET/MR, with PET/CT and the standard diagnostic pathway for preoperative staging in patients with breast cancer.
What Makes Our Research Exceptional?
Traditional diagnostic methods, such as mammography and ultrasound, are still widely used. However, the hybrid PET/MR technique combines anatomical and molecular imaging in a single examination, while whole-body magnetic resonance imaging (WBMR) allows assessment of the entire body without exposure to radiation.
In practice, this means:
- faster and more accurate diagnosis,
- the ability to tailor treatment to the individual patient’s needs,
- Reduction in the number of additional examinations.
Expertise and Scientific Credibility
The research conducted in our laboratory is supervised by Dr. Małgorzata Mojsak, a distinguished specialist in nuclear medicine and radiology, who serves as the principal investigator of the project.
Dr. Małgorzata Mojsak has extensive experience in conducting clinical studies related to cancer diagnostics, including the use of PET/MR technology and personalized tumor diagnostics. Her supervision ensures the highest scientific standards and patient safety throughout the study.
The project, conducted by the Medical University of Białystok and funded by the Medical Research Agency, contributes to the advancement of modern, personalized oncological diagnostics in Poland and represents an important step toward improving the effectiveness of breast cancer treatment.
A Common Objective: Promoting Women’s Health
European Breast Cancer Awareness Day is also an opportunity to encourage women to undergo regular preventive screenings and participate in clinical research. Such efforts enable the introduction of innovative methods that may become standard practice in cancer diagnosis and treatment in the future.
Our goal is for a breast cancer diagnosis to signify the start of effective treatment rather than a source of fear. Together, we can build a future in which modern diagnostics give patients a real chance for a full and healthy life.
Contact information:
phone number: 85 500 10 21
email: pet-rejestracja@bioskaner.eu
We strive to ensure that every woman has access to the best possible diagnostics and medical care.
